回到未来：癌症免疫治疗使用检查点抑制剂后多肌痛和多肌痛样综合征的识别与分类
Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors.
作者信息
Manzo Ciro, Isetta Marco
机构信息
Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine Department, Rheumatologic Outpatient Clinic Hospital "Mariano Lauro", Sant'Agnello, Italy.
Library and Knowledge Services, Central and North West London NHS Foundation Trust, London, United Kingdom.
出版信息
Reumatologia. 2021;59(1):62-63. doi: 10.5114/reum.2021.102600. Epub 2021 Feb 28.
Abstract
Polymyalgia rheumatica (PMR) and PMR-like syndromes are among the most frequent rheumatologic immuno-related adverse events (IRAEs) induced by cancer immunotherapy with "checkpoint inhibitors" (ICIs). Our short communication addresses two key methodological issues laid bare by published literature : 1) how to diagnose PMR and PMR-like syndromes following ICI therapy, 2) how PMR/PMR-like syndromes following ICI therapy are described as adverse drug reactions (ADRs).
摘要
风湿性多肌痛（PMR）和类PMR综合征是癌症免疫疗法使用“检查点抑制剂”（ICI）引发的最常见的风湿性免疫相关不良事件（IRAEs）。我们的简短通讯探讨了已发表文献中暴露的两个关键方法学问题：1）ICI治疗后如何诊断PMR和类PMR综合征，2）ICI治疗后的PMR/类PMR综合征如何被描述为药物不良反应（ADR）。
相似文献
1
Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors.回到未来：癌症免疫治疗使用检查点抑制剂后多肌痛和多肌痛样综合征的识别与分类
Reumatologia. 2021;59(1):62-63. doi: 10.5114/reum.2021.102600. Epub 2021 Feb 28.
2
Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature.免疫检查点抑制剂（ICI）治疗后风湿性多肌痛（PMR）及类PMR综合征的识别与分类：基于已发表文献系统评价所产生的讨论要点及灰色地带
Medicines (Basel). 2020 Nov 3;7(11):68. doi: 10.3390/medicines7110068.
3
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.免疫检查点抑制剂介导的风湿性多肌痛与原发性风湿性多肌痛：疾病特征和治疗需求的比较
Rheumatology (Oxford). 2025 Feb 1;64(2):771-779. doi: 10.1093/rheumatology/keae099.
4
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.免疫检查点抑制剂治疗后出现的类风湿关节炎和巨细胞动脉炎。
Ann Rheum Dis. 2017 Oct;76(10):1747-1750. doi: 10.1136/annrheumdis-2017-211216. Epub 2017 Jun 9.
5
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica.免疫检查点抑制剂相关性肌痛性多动脉炎。
Rheum Dis Clin North Am. 2024 May;50(2):255-267. doi: 10.1016/j.rdc.2024.02.001.
6
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.免疫检查点抑制剂引起的炎症性关节炎和巨细胞动脉炎的结局领域的识别：OMERACT irAE 工作组的范围综述。
Semin Arthritis Rheum. 2023 Feb;58:152110. doi: 10.1016/j.semarthrit.2022.152110. Epub 2022 Oct 26.
7
Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: working notes from a narrative review of published literature.风湿性多肌痛和多肌痛样综合征作为新冠病毒疫苗接种后的不良事件：来自已发表文献叙述性综述的工作笔记
Reumatologia. 2022;60(2):142-147. doi: 10.5114/reum.2022.115665. Epub 2022 May 18.
8
Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?诊断时炎症指标正常的风湿性多肌痛：我们能否更进一步？
Reumatologia. 2020;58(3):184-186. doi: 10.5114/reum.2020.96549. Epub 2020 Jun 29.
9
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature.免疫检查点抑制剂治疗相关肌痛性皮肌炎样综合征：病例系列及文献系统综述。
RMD Open. 2019 Apr 25;5(1):e000906. doi: 10.1136/rmdopen-2019-000906. eCollection 2019.
10
Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study.检查点抑制剂诱导的炎性关节炎及其他免疫相关不良事件的临床模式与随访：一项多中心研究
Front Med (Lausanne). 2022 Jun 15;9:888377. doi: 10.3389/fmed.2022.888377. eCollection 2022.
引用本文的文献
1
Are There Definite Disease Subsets in Polymyalgia Rheumatica? Suggestions from a Narrative Review.风湿性多肌痛是否存在明确的疾病亚组？一项叙述性综述的建议
Healthcare (Basel). 2025 May 23;13(11):1226. doi: 10.3390/healthcare13111226.
本文引用的文献
1
Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature.免疫检查点抑制剂（ICI）治疗后风湿性多肌痛（PMR）及类PMR综合征的识别与分类：基于已发表文献系统评价所产生的讨论要点及灰色地带
Medicines (Basel). 2020 Nov 3;7(11):68. doi: 10.3390/medicines7110068.
2
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.EULAR 针对癌症免疫治疗中使用检查点抑制剂引起的风湿免疫相关不良事件的诊断和管理的考虑要点。
Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.
3
Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature.免疫检查点抑制剂治疗相关肌痛性皮肌炎样综合征：病例系列及文献系统综述。
RMD Open. 2019 Apr 25;5(1):e000906. doi: 10.1136/rmdopen-2019-000906. eCollection 2019.
4
The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome.风湿性多肌痛作为副肿瘤综合征的真实证据。
Reumatismo. 2018 Mar 27;70(1):23-34. doi: 10.4081/reumatismo.2018.1031.
5
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的免疫相关不良事件。
N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.
6
[Polymyalgia rheumatica: diagnostic and therapeutic issues of an apparently straightforward disease.].[风湿性多肌痛：一种看似简单的疾病的诊断和治疗问题。]
Recenti Prog Med. 2017 May;108(5):221-231. doi: 10.1701/2695.27559.
7
Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set.风湿性多肌痛与癌症风险：诊断集的重要性。
Open Access Rheumatol. 2016 Oct 17;8:93-95. doi: 10.2147/OARRR.S116036. eCollection 2016.
8
2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.2012年风湿性多肌痛临时分类标准：欧洲抗风湿病联盟/美国风湿病学会合作倡议
Arthritis Rheum. 2012 Apr;64(4):943-54. doi: 10.1002/art.34356.
9
A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica.风湿性多肌痛诊断标准的敏感性比较
Ann Rheum Dis. 2005 Apr;64(4):626-9. doi: 10.1136/ard.2004.025296.
10
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
Zotero 插件